| New from NCI |
| Video—Colorectal Cancer Screening: What to Expect |
 |
|
Everyone over the age of 50 should be screened for colon and rectal cancer. Learn about the three screening methods that work to reduce the chance of death from colon and rectal cancer: colonoscopy, sigmoidoscopy, and home stool test. |
Experimental Drug Delays the Spread of Some Prostate Cancers
Read about results from a recent study that showed that the experimental drug darolutamide can help slow the spread of prostate cancer in some men with the disease. The drug also caused fewer side effects than similar prostate cancer drugs. |
Targeted Therapy and Immunotherapy Combination Effective for Kidney Cancer
Read about the results from two large clinical trials that are expected to change the usual treatment for many people with newly diagnosed advanced kidney cancer. |
| Revitalizing the Discovery of New Cancer Drugs from Natural Products |
 |
|
NCI has launched an ambitious initiative to make it easier for researchers to mine nature for leads on new cancer drugs. Learn about the Cancer Moonshot℠–funded NCI Program for Natural Products Discovery. |
HPV and Pap Testing
Learn about the current guidelines for cervical screening, the three testing options—HPV alone, Pap alone, and HPV and Pap testing together—and who should get which test how often. |
Bone Marrow Transplant Drug May Improve Immunotherapy for Metastatic Breast Cancer
A thick layer of connective tissue around some types of cancer cells acts as a barrier to immunotherapy. A new study used the bone marrow transplant drug plerixafor to thin this layer and improve how well immune checkpoint inhibitors worked in animal models of breast cancer.
|
| PDQ Summary Updates |
Adult Primary Liver Cancer Treatment
We’ve updated our PDQ summary on liver cancer with information about targeted therapy and immunotherapy as treatment options for stages C and D disease.
|
| Drug Information Updates |
Atezolizumab for Breast and Lung Cancers
We’ve updated our atezolizumab (Tecentriq) drug information summary to include two recent approvals by the Food and Drug Administration (FDA). Atezolizumab is now approved to treat triple-negative breast cancer that has the PD-L1 protein and extensive-stage small cell lung cancer. |
New Form of Trastuzumab for Breast Cancer
See our new drug information summary on trastuzumab and hyaluronidase-oysk (Herceptin Hylecta), which is approved by FDA to treat HER2-positive breast cancer. This combination drug is given under the skin, so treatment times are shorter than they are for trastuzumab alone. |
